Cargando…
Songling Xuemaikang capsules for patients with low-to-medium risk hypertension: study protocol for a randomized controlled trial
BACKGROUND: Hypertension is a major risk factor for cardio-cerebrovascular disease. Songling Xuemaikang capsules (SXC), a formulation of Chinese herbal patent medicine, has been used as a complementary medicine with conventional western medicine to treat patients with hypertension since 1994 in main...
Autores principales: | Jiang, Yuerong, Guo, Haiyan, Liu, Yue, Wang, Xin, Liang, Jiaqi, Xi, Ruixi, Bai, Ruina, Shi, Dazhuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466697/ https://www.ncbi.nlm.nih.gov/pubmed/30987658 http://dx.doi.org/10.1186/s13063-019-3308-5 |
Ejemplares similares
-
Neuronal protective effect of Songling Xuemaikang capsules alone and in combination with carbamazepine on epilepsy in kainic acid-kindled rats
por: Yang, Haiyan, et al.
Publicado: (2019) -
miR-941 as a promising biomarker for acute coronary syndrome
por: Bai, Ruina, et al.
Publicado: (2017) -
Adhesive capsulitis of the shoulder: protocol for the adhesive capsulitis biomarker (AdCaB) study
por: Page, Richard S., et al.
Publicado: (2019) -
Effects of Qingda granule on patients with grade 1 hypertension at low-medium risk: study protocol for a randomized, controlled, double-blind clinical trial
por: Long, Lin-zi, et al.
Publicado: (2023) -
Effects of Bushen-Jiangya granules on blood pressure and pharmacogenomic evaluation in low-to-medium-risk hypertensive patients: study protocol for a randomized double-blind controlled trial
por: Yang, Xiaochen, et al.
Publicado: (2022)